These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 34379772)

  • 21. Peptide Receptor Radionuclide Therapy in Patients With Differentiated Thyroid Cancer: A Meta-analysis.
    Lee DY; Kim YI
    Clin Nucl Med; 2020 Aug; 45(8):604-610. PubMed ID: 32520503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical relevance of
    Saponjski J; Macut D; Saranovic DS; Radovic B; Artiko V
    Radiol Oncol; 2020 Nov; 55(1):18-25. PubMed ID: 33885241
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma.
    Treglia G; Castaldi P; Villani MF; Perotti G; de Waure C; Filice A; Ambrosini V; Cremonini N; Santimaria M; Versari A; Fanti S; Giordano A; Rufini V
    Eur J Nucl Med Mol Imaging; 2012 Apr; 39(4):569-80. PubMed ID: 22223169
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Role of 68 Ga-DOTA-SSA PET/CT in the Management and Prediction of Peptide Receptor Radionuclide Therapy Response for Patients With Neuroendocrine Tumors : A Systematic Review and Meta-analysis.
    Lee ONY; Tan KV; Tripathi V; Yuan H; Chan WW; Chiu KWH
    Clin Nucl Med; 2022 Sep; 47(9):781-793. PubMed ID: 35485851
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Application of 68Ga-Somatostatin Analog and 18F-FDG PET/CT for Bone Metastasis from Neuroendocrine Tumors.
    Bai L; Xu J; Xu X; Zhang J; Liu X; Hu S; Chen J; Song S
    Neuroendocrinology; 2024; 114(8):775-785. PubMed ID: 38824926
    [TBL] [Abstract][Full Text] [Related]  

  • 26. (68)Ga-DOTA-peptide: A novel molecular biomarker for nasopharyngeal carcinoma.
    Khor LK; Loi HY; Sinha AK; Tong KT; Goh BC; Loh KS; Lu SJ
    Head Neck; 2016 Apr; 38(4):E76-80. PubMed ID: 26275126
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early response assessment and prediction of overall survival after peptide receptor radionuclide therapy.
    Huizing DMV; Aalbersberg EA; Versleijen MWJ; Tesselaar MET; Walraven I; Lahaye MJ; de Wit-van der Veen BJ; Stokkel MPM
    Cancer Imaging; 2020 Aug; 20(1):57. PubMed ID: 32778165
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Feasibility and Therapeutic Potential of Combined Peptide Receptor Radionuclide Therapy With Intensive Chemotherapy for Pediatric Patients With Relapsed or Refractory Metastatic Neuroblastoma.
    Fathpour G; Jafari E; Hashemi A; Dadgar H; Shahriari M; Zareifar S; Jenabzade AR; Vali R; Ahmadzadehfar H; Assadi M
    Clin Nucl Med; 2021 Jul; 46(7):540-548. PubMed ID: 33782280
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of (68)Ga-DOTATATE and (18)F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma.
    Conry BG; Papathanasiou ND; Prakash V; Kayani I; Caplin M; Mahmood S; Bomanji JB
    Eur J Nucl Med Mol Imaging; 2010 Jan; 37(1):49-57. PubMed ID: 19662413
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls.
    Beukhof CM; Brabander T; van Nederveen FH; van Velthuysen MF; de Rijke YB; Hofland LJ; Franssen GJH; Fröberg LAC; Kam BLR; Visser WE; de Herder WW; Peeters RP
    BMC Cancer; 2019 Apr; 19(1):325. PubMed ID: 30953466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence of hitherto unknown brain meningioma detected on
    Parghane RV; Talole S; Basu S
    World J Nucl Med; 2019; 18(2):160-170. PubMed ID: 31040748
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of tumour biomarkers in choosing the appropriate positron emission tomography imaging in follow-up of medullary thyroid cancer.
    Şahin E; Elboğa U
    J Med Imaging Radiat Oncol; 2020 Dec; 64(6):756-761. PubMed ID: 32656989
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy.
    Werner RA; Ilhan H; Lehner S; Papp L; Zsótér N; Schatka I; Muegge DO; Javadi MS; Higuchi T; Buck AK; Bartenstein P; Bengel F; Essler M; Lapa C; Bundschuh RA
    Mol Imaging Biol; 2019 Jun; 21(3):582-590. PubMed ID: 30014345
    [TBL] [Abstract][Full Text] [Related]  

  • 35. THE COMBINED USE OF CALCITONIN DOUBLING TIME AND
    Yang JH; Camacho CP; Lindsey SC; Valente FOF; Andreoni DM; Yamaga LY; Wagner J; Biscolla RPM; Maciel RMB
    Endocr Pract; 2017 Aug; 23(8):942-948. PubMed ID: 28614009
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of ⁶⁸Ga-DOTATATE PET-CT, ¹⁸F-FDG PET-CT and 99mTc-(V)DMSA scintigraphy in the detection of recurrent or metastatic medullary thyroid carcinoma.
    Ozkan ZG; Kuyumcu S; Uzum AK; Gecer MF; Ozel S; Aral F; Adalet I
    Nucl Med Commun; 2015 Mar; 36(3):242-50. PubMed ID: 25369749
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peptide receptor radionuclide therapy (PRRT) in metastatic neuroendocrine tumors of unknown primary (CUP-NETs).
    Baum RP; Wang P; Jakobsson V; Zhao T; Schuchardt C; Khong PL; Zhang J
    Theranostics; 2024; 14(1):133-142. PubMed ID: 38164147
    [No Abstract]   [Full Text] [Related]  

  • 38. Highly favourable outcomes with peptide receptor radionuclide therapy (PRRT) for metastatic rectal neuroendocrine neoplasia (NEN).
    Kong G; Grozinsky-Glasberg S; Hofman MS; Akhurst T; Meirovitz A; Maimon O; Krausz Y; Godefroy J; Michael M; Gross DJ; Hicks RJ
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):718-727. PubMed ID: 30343432
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of Wandering Masses and Tumor Heterogeneity on
    Baberwal P; Parghane R; Basu S
    J Nucl Med Technol; 2024 Sep; 52(3):272-273. PubMed ID: 39237338
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of PET-CT scan with somatostatin analogue labelled with gallium-68 (⁶⁸Ga-DOTA-TATE PET-CT) in diagnosing patients with disseminated medullary thyroid carcinoma (MTC).
    Pałyga I; Kowalska A; Gąsior-Perczak D; Tarnawska-Pierścińska M; Słuszniak J; Sygut J; Góźdź S
    Endokrynol Pol; 2010; 61(5):507-11. PubMed ID: 21049467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.